Role of G protein-coupled receptor kinase 2 in tumoral angiogenesis

Verónica Rivas1,2, Laura Nogués1,2, Clara Reglero1,2, Federico Mayor Jr1,2, and Petronila Penela1,2,*

1Departamento de Biología Molecular and Centro de Biología Molecular “Severo Ochoa” (Consejo Superior de Investigaciones Científicas - Universidad Autónoma de Madrid); Universidad Autónoma de Madrid; Madrid, Spain; 2Instituto de Investigación Sanitaria La Princesa; Madrid, Spain

Keywords: angiogenesis, ALK1 signaling, cancer, GRK2, PDGF-BB, tumor-associated macrophage, vascular maturation

Abbreviations: ALK, activin receptor-like kinase; Ang2, angiopoietin 2; AR, adrenergic receptor; BMP, bone morphogenetic protein; EC, endothelial cell; FGF, fibroblast growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HUVEC, human umbilical vein endothelial cell; IH, infantile hemangioma; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; S1P, sphingosine-1-phosphate; TGFβ1, transforming growth factor beta 1; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; VSMC, vascular smooth muscle cell.

Vascular networks play an essential role in maintaining the homeostasis and growth of vertebrate organisms, and the somewhat complex process of angiogenesis is essential for vessel formation during embryonic development and physiological tissue remodeling.1 Multiple cell types participate in physiological angiogenesis, during which numerous signaling pathways must be engaged and coordinated precisely through independent and interdependent factors. However, angiogenesis is induced aberrantly in association with inflammation or tumors. Indeed, the tumor microvasculature is usually very angiogenic and leaky, with enlarged and dilated vessels that are lined with immature tumor microvasculature.

Downregulation of G protein-coupled receptor kinase 2 (GRK2) in endothelial cells has recently been identified as a relevant event in the tumoral angiogenic switch. Based on the effects of altering GRK2 dosage in cell and animal models, this kinase appears to act as a hub in key signaling pathways involved in vascular stabilization and remodeling. Accordingly, decreased GRK2 expression in endothelial cells accelerates tumor growth in mice by impairing the pericytes ensheathing the vessels, thereby promoting hypoxia and macrophage infiltration. These results raise new questions regarding the mechanisms by which transformed cells trigger the decrease in GRK2 observed in human breast cancer vessels and how GRK2 modulates the interactions between different cell types that occur in the tumor microenvironment.

Vascularization

GRK2 Regulates Physiological and Tumor Vascularization

G protein-coupled receptor kinases (GRKs) were initially identified as key players in the desensitization and internalization of multiple G protein-coupled receptors (GPCRs). In addition to such canonical roles, GRKs also promote G protein-independent transduction cascades downstream of GPCRs and initiate alternative signaling pathways by phosphorylating and/or interacting with partners other than GPCRs. Although the current GRK2 “interactome” includes several potential modulators of vascular homeostasis and remodeling, only recently has this kinase been shown to be necessary for vessel formation and stability. Angiogenesis involves several early morphogenetic steps, during which endothelial cells (ECs) polarize, migrate, establish cell–cell contacts, and form vessel lumens. These events are followed by a stabilization step that is driven by pericycle apposition.1 Upon GRK2 downmodulation the behavior of primary microvascular ECs is altered, as characterized by an increase in motility and enhanced downstream signaling in response to key proinflammatory activities, further fostering abnormal vascularization and inflammation. In such a harsh microenvironment, transformed cells often became more aggressive, displaying increased proliferation, invasiveness, and drug resistance.2 Through reciprocal interactions in the tumor-associated vasculature, tumor-infiltrated immune cells and transformed cells emerge as fundamental factors underlying cancer progression.

© Veronica Rivas, Laura Nogués, Clara Reglero, Federico Mayor Jr, and Petronila Penela
*Correspondence to: Petronila Penela; Email: ppenela@cbm.csic.es
Submitted: 06/16/2014; Revised: 08/22/2014; Accepted: 08/23/2014
http://dx.doi.org/10.4161/23723548.2014.969166
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

© Landes Bioscience
angiogenic stimuli such as vascular endothelial growth factor (VEGF), sphingosine-1-phosphate (S1P), or serum. Similarly, these cells lose the capability to organize into tubular structures and the balanced secretion of proinflammatory and proangiogenic factors is disrupted.

Endothelial GRK2 dosage modulates transforming growth factor beta 1 (TGFβ1)-mediated pathways. TGFβ1 is fundamental for the activation and resolution of angiogenic events because diverse angiogenic stimuli control its production and secretion, and TGFβ itself upregulates other key angiogenic modulators. The cellular responses triggered by TGFβ1 in ECs are complex and contribute positively or negatively to endothelial activation, in part due to the co-existence of 2 receptors that drive opposite effects, activin receptor-like kinase 1 (ALK1) and ALK5, and their functional cross-modulation. In this scenario, GRK2 levels can alter the balance in TGFβ1 signaling through ALK5 and ALK1 receptors (see below). Consistent with this array of cell-autonomous endothelial defects, neovascularization is impaired in both global and endothelium-specific GRK2 knockout mice. In experimental models of angiogenesis, loss of GRK2 compromises the ability of ECs to differentiate and fuse into tubular structures and the adherence of pericytes required for the formation of structured vessels. In more physiological settings, such as embryonic or postnatal retinal neovascularization, mice with a global or endothelium-specific deficit of GRK2 develop vessels with altered morphometrics and reduced mural coating. In the mouse retina, GRK2 depletion causes delayed remodeling of the primary plexus, which has an excessive vascular density and abnormal endothelial-pericyte interactions that might impede effective pruning. Remarkably, a reduced level of GRK2 in the endothelium accelerates tumor growth in mice, in addition to increasing the size of intratumoral vessels, reducing pericyte coverage, and enhancing macrophage infiltration, thereby strengthening many of the known hallmarks of the tumor microvasculature.

**GRK2 at the Crossroads of Endothelial Activation and Vascular Maturation**

The dynamic expression of GRK2 in the endothelium of the developing vasculature suggests that it fulfills a pivotal role in vascular maturation and maintenance, as does its ability to regulate key signaling pathways downstream of platelet-derived growth factor (PDGF), TGFβ1, and bone morphogenetic protein 9 (BMP9) receptors that are engaged in vascular stabilization and remodeling. Indeed, the immature vascular phenotype associated with GRK2 deficiency further corroborates this role. The cellular dosage of GRK2 is important in determining how ECs respond to different physiological stimuli, such as VEGF, fibroblast growth factor (FGF), PDGF, or TGFβ, which orchestrate not only the functional specification of activated ECs, but also their maturation (Fig. 1). This dynamic interplay and the balance of the “tip” and “stalk” EC ratio are central to angiogenic activation. Such aspects are defined upon VEGF activation of ECs in pre-existing vessels through Notch-mediated cell fate determination. Thus, VEGF upregulates the Notch ligand Delta-like 4 (Dll4), which mediates lateral inhibition of VEGF signaling in neighboring cells by downregulating VEGFR2 and upregulating VEGFR1, a decoy receptor for the VEGF ligand. As a result, a graded response to VEGF is established in which the less common high responding cells become tip cells and sprout toward the source of VEGF, while most of the adjacent cells are instructed to become weaker responders and convert to stalk cells that follow the guiding tip cell and proliferate. However, vessels in the tumor microenvironment are leaky and immature as a result of their exposure to high levels of VEGF-A derived from tumor cells, endothelial cells, and platelets. Such abnormal vascularization is related to the negative and positive effects of VEGF on PDGF-induced pericyte chemotaxis and differentiation and sprouting activity, respectively. GRK2-deficient ECs do not produce more VEGF-A but they do display enhanced VEGF-dependent downstream signaling and chemotactic responses. It is tempting to speculate that GRK2 downmodulation could simulate the effects of an excessive and chronic VEGF challenge in tumors that are poorly equipped with this angiogenic factor.

In addition to the potential impact on VEGF signaling, GRK2 also influences secretion of endothelial PDGF-BB, a factor that regulates several steps in vessel formation. During angiogenesis, PDGF-BB expression is restricted to immature capillary structures (angiogenic sprouts) and is concentrated in the tip ECs. Although the primary vascular target cells for PDGF-BB are pericytes and vascular smooth muscle cells (VSMCs), the endothelium also responds to this factor as FGF2-activated ECs can upregulate PDGFR receptors for autocrine PDGF-BB stimulation. Such autocrine regulation, although not well characterized, has been related to increased sprouting and remodeling, proliferation, morphological reorganization, and anastomosis of ECs (for a review see ref. 15). Since PDGF-BB secretion is enhanced by GRK2 downmodulation in ECs, this could exacerbate the “tip” cell character in ECs and augment the number of unstable and immature vessels. This scenario is consistent with the role of GRK2 as a desensitizer of PDGFR in VSMCs, whereby downregulation of PDGFR-B signaling is a prerequisite for the maturation of ECs. However, the most relevant functions of PDGF-BB are as a potent recruiter of mural cells and in the promotion of pericyte/VSMC coverage of nascent vessels. Secretion and periendothelial retention of PDGF-BB must be tightly regulated to form the proper chemotactic-like gradients that efficiently guide pericytes to nascent vessels and thereafter ensure their stable apposition. The higher levels of PDGF-BB secreted by GRK2-deficient ECs might disturb such local gradients, contributing to the dissociation of pericytes from the vessel in both xenograft tumors and in the developing and normal adult tissues of mutant mice.

Abnormal PDGF-BB secretion by GRK2-deficient ECs could be secondary to improper tip/stalk specification, or may reflect GRK2-mediated impairment of signaling pathways engaged in its synthesis. Downmodulation of GRK2 stimulates the ALK5-dependent Smad2/3 phosphorylation branch of the TGFβ1 signaling pathway (Fig. 1), which is reported to promote PDGF-BB transcription. The enhanced stimulation of ALK5-dependent Smad2/3 phosphorylation observed in GRK2−/− ECs...
could be explained by the previously reported direct inhibitory effect of GRK2 on Smad2/3 activity as a result of GRK2-mediated phosphorylation of these factors within the linker domain. Conversely, a decrease in GRK2 markedly impairs the ALK1-Smad1/5 branch in response to either TGFβ1 or the ALK1-specific BMP9 ligand, a member of the TGFβ family that influences vascular quiescence. Therefore, GRK2 levels are able to modulate TGFβ1-mediated ALK1/ALK5 pathways in endothelial cells by both inhibiting the ALK5 route at the level of Smad2/3 and by positively contributing to the activation of the ALK1 route through an uncharacterized mechanism. Upon GRK2 downmodulation, both relief of the direct inhibition of Smad2/3 and decreased ALK1 signaling-mediated lateral inhibition of the ALK5 pathway would contribute to the observed unbalance in TGFβ1 signaling toward the ALK5 route. ALK1 signaling is involved in maturation events such as arteriovenous specification of developmental vasculature, mural recruitment, and adult vessel homeostasis. Vascular malformations detected upon GRK2 downregulation might affect all of these ALK1-regulated processes. In addition, the reduction in GRK2 could influence the crosstalk between ALK1 and Notch that is involved in endothelial fate selection and the differentiation of periendothelial cells. In particular, BMP9 activity on stalk cells stimulates Smad1/5 and its downstream gene expression, including Notch targets that prevent tip cell specification and the migration of ECs. Thus, both ALK1 and Notch cascades cooperate in maintaining the stalk cell fate of EC cells, which will ultimately undergo a process of tubulogenesis to form vessels. Inhibition of the tumor upregulated Notch ligand Dll4 results in excessive tip cell formation and proliferation, formation of immature vessels, and tissue ischemia, resembling the effects of GRK2 downmodulation. ALK1 activation also counteracts FGF-induced EC proliferation and VEGF-stimulated angiogenesis, making it tempting to speculate that ECs with little GRK2 might be prone to adopt a tip phenotype as a result of weaker ALK1/Notch synergy and stronger ALK1/VEGF antagonism during EC commitment.

Figure 1. Endothelial-specific loss of GRK2 impairs maturation and vascular remodeling in adult and developmental angiogenesis. (A) Functional angiogenesis encompasses several sequential and interdependent steps that require proper control of GRK2 expression. The initial activation phase involves perivascular cell detachment from pre-existing vessels, and the specification of activated endothelial cells into tip and stalk populations as a result of the integration of VEGF, ALK1, and PDGF signals with the Notch pathway. During the resolution phase, ECs cease to migrate and proliferate and, instead, initiate tubulogenesis and membrane basement formation. Downmodulation of GRK2 deregulates the downstream signaling to such co-operating factors of endothelial specification, which might alter tip/stalk specification and/or the maintenance of activated ECs. Vessel maturation and remodeling also occur in the resolution phase, as mural cells are recruited for endothelial tube investment. Increased secretion of the mural cell attractant PDGF by GRK2-deficient endothelial cells could disturb the local gradients needed to drive adequate intercellular apposition of pericytes with ECs. (B) GRK2 regulates the TGFβ-dependent state of the endothelium via simultaneous modulation of the ALKS and ALK1 pathways. GRK2 downmodulation not only decreases direct inhibition of Smad2/3 (in a kinase activity-dependent manner) but could also alleviate ALK1 signaling-mediated lateral inhibition of the ALK5 pathway. Stronger activation of ALKS with concurrent attenuated ALK1 signaling might alter the balance between the activation and resolution phases of angiogenesis, thereby impairing sprouting and maturation. ALK, activin receptor-like kinase; EC, endothelial cell; PDGF, platelet-derived growth factor; TGFβ1, transforming growth factor beta 1; VEGF, vascular endothelial growth factor.
However, GRK2-deficient ECs do not behave as “full” tip cells, as suggested by the impaired sprouting and the reduced branching and filopodia formation at early developmental stages of retinal vasculature. This is probably related to the fact that GRK2 also influences other angiogenic pathways. In this regard, GRK2 downmodulation could simultaneously strengthen the restrictive effect of the ALK5-Smad2/3 signaling branch on sprouting. 29 Overall, these results support the concept that GRK2 is a central regulator of endothelial activation and vessel maturation, representing a common signaling hub for different effector pathways operating in distinct steps of angiogenesis.

How Does the Tumor Milieu Instruct Endothelial Cells to Express Less GRK2?

Endothelial GRK2 protein expression is diminished in vessels of human breast cancer but not in benign lesions, which correlates with the increased vascular tortuosity, permeability, and pericyte depletion in tumors. Poor vascular remodeling might adversely skew progression toward malignancy and metastasis, and this may be actively determined by systemic hormonal and stress conditions, the stromal microenvironment of the tumor and, ultimately, by transformed cells. 30-32 In this regard, conditioned media from either melanoma or human breast cancer cell lines of luminal or basal-like lineages, but not that from normal mammary cells, significantly reduces the endothelial GRK2 dosage. 6 Moreover, GRK2 is downregulated in activated human microvascular ECs that are co-cultured with human colorectal cancer cells in the presence of blood components. 6 Interestingly, although these data suggest that aberrant vascular expression of GRK2 might be a common feature of cancer, this may not be the case for all types of cancer. Indeed, different tumor cells display a distinct ability to downmodulate endothelial GRK2, which is triggered by LS180 but not by HT-29 colon cancer cells, and is triggered more rapidly and potently by MCF7 than by Hs578T breast cancer cells. We speculate that such variability might have implications in the clinical outcome of different tumors.

Influence of the proinflammatory milieu of transformed cells and the intratumor immune cell infiltrate

Despite evidence that GRK2 expression is downmodulated at the transcriptional level, there is little information available about the mechanisms that govern this process. 33,34 Analysis of the human GRK2 gene promoter in aortic smooth muscle cells revealed that transcription is enhanced by factors related to vasoconstriction downstream of the GPCR-Gq signaling pathways, 35 whereas proinflammatory mediators such as interleukin (IL)-1β, tumor necrosis factor (TNF)α, and interferon (INF)γ have the opposite effect. Interestingly, IL-1β and TNFα are often released by tumor cells in response to local hypoxia (Fig. 2). However, other tumor factors released in relation to the transforming phenotype could also be implicated in the paracrine regulation of GRK2. 36 Identification of the tumor-secreted factors that influence vascular GRK2 expression is an interesting goal for future studies.

In addition, transformed cells interact in a paracrine manner with distinct non-neoplastic components of the tumor, mainly fibroblasts and immune cells, which leads to a “smoldering” inflammation state that encourages cancer cell proliferation and survival. 37,38 Secretion of diverse chemokines and VEGF-A by tumor cells attracts myeloid cells, which in turn release a cocktail of cytokines (including TNFα, IL-1β, and IL-6) that could directly reduce GRK2 transcription in ECs. Moreover, inflammatory mediators appear to affect post-transcriptional regulation of GRK2 protein and its activity. Thus, autacoids such as reactive oxygen species (ROS), nitric oxide (NO), and low-molecular-weight S-nitrosothiols (SNO) are actively released by infiltrating proinflammatory macrophages at earlier stages of tumor growth and can inhibit GRK2 translation 39 and catalytic activity by means of protein S-nitrosylation. 40 In addition, cytokines whose levels are increased by the tumor, such as IL-6, promote proteasome-dependent degradation of GRK2 in blood peripheral mononuclear cells. 33,41 Furthermore, proteasome-dependent GRK2 downmodulation was noted upon acute exposure of brain organotypic cultures to hypoxia/ischemia 42 and in human umbilical vein endothelial cells (HUVECs; personal observations). Since GRK2 ubiquitination and proteasomal turnover is enhanced by several receptors (including the β2AR receptor, see below) through a mechanism involving GRK2 phosphorylation by c-Src or MAPK, 43,44 it is also possible that activation of these pathways in the EC tumor context may trigger kinase reduction.

Thus, it is tempting to suggest that the relationship between inflammation and vascular GRK2 might constitute a self-perpetuating pathological cycle that fosters tumor progression. The vessel dysfunction promoted by GRK2 downmodulation would trigger stronger hypoxia and myeloid infiltration, which in turn would drive further endothelial GRK2 depletion. In this scenario, the use of antitumoral antioxidant compounds to curtail this aberrant cycle and “normalize” the tumor vasculature could prove to be a useful approach.

Influence of tumor stress associated with activity of the sympathetic nervous system

Behavioral stress is another tumor-related event that could regulate vascular GRK2 expression. Cumulative evidence indicates that chronic neurosympathetic activity affects the activity of the immune system, 45 as well as the malignant growth and dissemination of tumor cells, through direct stimulation of β2-adrenergic receptors (ARs). 45,46 Several processes appear to underlie the influence of βARs on tumor progression, including myeloid recruitment or increased proinflammatory secretion, and angiogenesis triggered by adrenergic stimulation of tumor and immune cells. 47 It is tempting to suggest that exposure of tumor vessels to circulating adrenaline (released by the adrenal medulla) or, more significantly in a tumor context, to tissue ischemia-induced norepinephrine release from the sympathetic nerves, 47,48 might influence endothelial cells and the expression of GRK2. The interplay between βAR signaling and vascular GRK2 expression has mainly been studied in the context of cardiovascular and macrovasculature homeostasis. 49,50 The level of circulating catecholamines and βAR activity correlates positively with GRK2 protein and mRNA expression in different tissues and
cell types. These effects seem to be mediated by β1AR activation as β1AR (but not β2AR) transgenic mice display increased levels of GRK2. In contrast, stimulation of β2AR triggers GRK2 protein degradation in a diversity of cell types. Although it has not been directly tested, it is tempting to suggest that the sympathetic tumoral stress acting through β2AR could reduce GRK2 expression in endothelial cells (thus exacerbating pathological features of the tumor vasculature).

βAR activation appears to be involved in the stimulation of proliferation of both adult and circulating EC precursor cells and in functional neoangiogenesis by means of VEGF stimulation. In contrast, defective βAR expression impairs the vascularization of damaged tissue, suggesting that tight control of adrenergic activity is needed to integrate angiogenic responses in injury and repair. In keeping with this, β-blockers have been suggested to play a protective role in reducing the incidence of all cancer types through their influence in tumor angiogenesis by inhibiting β2AR receptor-mediated effects on both malignant cells and tumor vessels; however, the extent of such protection varies among tumors, and moreover shows no relationship with clinical outcome in some cohorts of breast cancer patients. These discrepancies might be related to different off-target β2AR affinities of the most commonly used selective β1-blockers, the distinct proportion and dosage of receptor subtypes in βAR-bearing tumoral and endothelial cells within a particular tumor, and/or the different relative influence of βAR-mediated effects on the behaviour of malignant cells versus the tumor microenvironment in tumor growth and progression. Remarkably, infantile hemangiomia (IH), which results from abnormal proliferation of endothelial cells, has been shown to be effectively treated with non-selective β-blockers such as propranolol. These benign vascular neoplasms are characterized by densely packed endothelial and pericyte cells that form immature vessels resembling those resulting from GRK2 downmodulation. Hemangioma-derived endothelial cells (HemECs) are rounded in shape and display increased growth and migratory properties, whereas proliferative pericytes show a diminished ability to adhere to and stabilize blood vessels. Moreover, HemECs appear to be more sensitive to paracrine/external stimulation by VEGF-A, and the proliferating phase of IH is paralleled by excessive VEGF production and increased VEGFR-2 activity, which are partially dependent on β2AR signaling. Based on these features it is tempting to suggest that HemECs may express reduced GRK2 levels and that the effects of propranolol on vessel stabilization may be partially mediated by upregulation of this kinase. However, in the context of other tumor pathologies, the effects of βAR challenge (and β-blocker therapy) on endothelial GRK2 might be not straightforward, depending on the particular targeted cell type (tumoral versus stromal components), cell microenvironment conditions (hypoxic, inflamed, or tumoral), the specific adrenergic ligand (epinephrine versus norepinephrine), or the relative abundance of the βAR subtypes, which may distinctly affect the signaling pathways related to protein kinase degradation.

**GRK2 and Tumor Angiogenesis: Beyond Endothelial Regulation**

Although our results highlight the vascular bed as the main functional target, other cellular components of the tumor stroma could contribute to GRK2-dependent malignant phenotypes.
In this regard, infiltration of immune cells into the tumor microenvironment is a critical event in cancer progression. Interestingly, tumor progression is enhanced in global systemic GRK2 hemizygous mice, a model in which other cell types besides endothelial cells also have diminished GRK2. Notably, despite showing similar endothelial expression of GRK2, tumor growth is greater in Tie2Cre-GRK2fl/fl than in Tie2Cre-GRK2fl/fl mice (Table 1), suggesting that differences in growth may also rely on non-endothelial host components, such as macrophages. Indeed, these cells are major inflammatory components associated with malignant tumors and although their conventional role is to combat pathogens and to assist in adaptive immune responses, in most cases they enhance tumor cell proliferation and invasion. Circulating monocytes are actively recruited into damaged tissues where they specifically differentiate into 2 major states with different activities depending on local cues: the classically activated (M1)-polarized macrophages that are cytotoxic to microbes or malignant cells and stimulate the lymphocyte immune responses or the alternatively activated (M2)-polarized macrophages involved in immunosuppression and wound healing/tissue repair. In the tumor milieu, monocytes lean toward a differentiation state that shares similarities with the M2-polarized macrophages, thereby displaying potent immunosuppressive, proangiogenic, and protumoral properties.

**Effect of endothelial GRK2 dosage on tumor macrophage recruitment**

Specific signals recruit monocytes and guide them into the hypoxic areas of the tumor; indeed, the highest density of tumor-associated macrophages (TAMs) is found in such hypoxic foci in breast and other tumors. These foci are created by the confluence of a dysfunctional microvasculature, which limits the oxygen supply, and the presence of nearby tumor cells with high rates of oxygen consumption. In these hypoxic areas, TAMs no longer fulfill inflammatory/cytotoxic roles but, rather, are committed to adopt a protumoral M2-like behavior. Both monocyte recruitment and hypoxia-induced commitment of macrophages appear to be fostered not only by endothelial GRK2 downmodulation but also by the GRK2 monocyte dosage. Several CC chemokines that act through GPCRs and are produced by tumor cells, fibroblasts, and ECs specifically attract and activate mononuclear cells, with CCL2 or CCL5 being those most widely implicated in human breast and melanoma cancer. However, other chemoattractants may also be involved, such as VEGF, the endothelins ET1 or ET2, and those produced by activated macrophages such as CCL4, colony-stimulating factor-1, or CXCL8.

Reduced GRK2 expression alters the endothelial production of several of these factors and might help recruit monocytes to tumors, as indicated by the stronger presence of macrophages in

![Diagram](image-url)
cancer lesions that develop in endothelial GRK2-specific-knockout mice and by the enhanced monocyte chemotaxis produced by the EC-derived secretome from these mice.6 Thus, higher levels of potent macrophage chemotactants, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), placental growth factor 2 (PIGF2), Factor III, or CXCL16, are produced by GRK2+/− mouse lung ECs,6 while there is also an increase in the factors that facilitate monocyte adhesion and extravasation through endothelial layers, such as CXCL12 and ET-1.63 In addition, secretion of the CXCR2 ligand KC (CXCL1) in the conditioned media of these cells is strongly upregulated, which is involved in monocyte chemotaxis and arrest on the endothelium as well as flow and extravasation.65 Within the tumor mass, macrophages seem to follow a gradient of hypoxia-induced chemokine secretome such as VEGF, CXCL8, or ET2, which are mainly produced by tumor cells.62 In summary, endothelium-specific downmodulation of GRK2 could favor the recruitment of macrophages to discrete regions of the tumor by direct (EC secretome) and indirect (leaky vessels leading to hypoxia) mechanisms, thereby fueling tumor growth.

**GRK2 and chemotactic responses of myeloid cells**

Monocytes/macrophages from systemic GRK2 hemizygous mice may display more potent chemotactic responses toward tumor-derived homing signals, which might contribute to the more effective growth of tumors in GRK2+/− and Tie2Cre-GRK2fl/fl mice than in Tie2Cre-GRK2fl/+ and Tie2Cre-GRK2fl/fl mice (Table 1). GRK2 is known to play an important role in the motility of immune cells and is expressed strongly in different types of immune cells, representing an important regulator of the T lymphocyte, macrophage, and neutrophil responses during inflammation.66 Consistent with the “classic” role of GRK2 in GPCR desensitization, reduction of its expression significantly enhances the chemotactic response of lymphocytes and neutrophils toward CCR5, CCR2, CXCR2, and chemotactic receptors for substance P, S1P, or formyl-peptides.66,67 Several reports have reflected the inability of neutrophils with increased GRK2 levels to migrate toward CXCL2 or CXCL8 chemotactants,68 while mobilization of macrophages from global GRK2 hemizygous mice to CCL5 is enhanced.69 Interestingly, lipopolysaccharide activation of TLR4 favors CCL2-induced migration of macrophages by disengaging GRK2-dependent CCR2 receptor desensitization.70 Overall, it is tempting to suggest that the concurrent downmodulation of GRK2 in vascular endothelial cells and circulating monocytes might foster further tumor growth (Table 1).

Interestingly, ECs and macrophages share common precursor progenitors of myeloid origin during embryonic development, suggesting that Tie2-driven recombinase activation and GRK2 depletion would affect both cell types at some point in their differentiation. Despite the fact that expression of GRK2 in macrophages from Tie2-Cre/GRK2fl/fl mice is no different from that in wild-type animals,71 supporting the importance of the endothelial component in the differential growth of tumors observed in this animal model, it is still possible that in a pathological setting, minor myeloid Tie2-positive lineages would be selectively mobilized to participate in tumor growth. In fact, a subset of circulating Tie2-expressing monocytes (TEMs) has been shown to represent a relevant proportion of the tumor immune cellular infiltrate distinct from TAMs.32,72 TEMs are a rare cell population in normal tissues but they actively home to the tumor stroma in response to Ang2, a Tie2-ligand produced by activated ECs and angiogenic vessels. Selective depletion of TEMs inhibits tumor angiogenesis and causes tumor regression despite the presence of TAMs, suggesting that TEMs are critical for the tumor angiogenic switch. It has been proposed that, in addition to Ang2, TEMs might use tumor-secreted non-inflammatory mediators other than those used by TAMs to be guided into avascular, non-inflamed tumor regions. It is tempting to suggest that low levels of GRK2 could facilitate the chemotaxis of these cells toward some relevant cues, as occurs in the migration of macrophages toward inflammatory mediators. Changes in GRK2 expression levels by TEMs (or TAMs) might modulate the tumor homing of these cellular populations and the outcome of tumor progression, an interesting issue to address in future studies.

**A role for GRK2 in macrophage polarization?**

Finally, decreased expression of GRK2 in the tumoral vascular bed and/or the myeloid infiltrate might also influence the phenotypic TAM commitment. Although M2 marker-based characterization of TAMs has not been addressed in tumors grown in Tie2Cre-GRK2fl/fl mice, the higher levels of adrenomedullin in the

### Table 1. Tumor growth in different mouse models with global or endothelial-specific alterations in GRK2 levels

| Mouse model | Expected dosage of GRK2 (according to the wild-type alleles of ADRBK1 gene) | Syngenic xenograft melanoma tumor |
|-------------|-------------------------------------------------|-----------------------------------|
|             | Endothelial component | Macrophage component | Tumor size*, mm³ (mean ± SEM) |
| GRK2+/+     | ++                  | ++                  | 172 ± 22                        |
| GRK2+/−     | +                   | +                   | 822 ± 158††                   |
| Tie2Cre-GRK2fl/fl | −                   | +                   | 1,300 ± 281§§                 |
| Tie2Cre-GRK2fl/+ | −                  | ++                  | 658 ± 8§§                      |
| Tie2Cre-GRK2fl/+ | +                  | ++                  | 363 ± 160§§                   |

*14 days after implantation, n = 4–9 mice
†p < 0.05; ††p < 0.001 compared to GRK2+/+ mice
§p < 0.05, §§p < 0.05 compared to GRK2+/− mice. Data adapted from Rivas et al.6
Role of Other GRKs in Tumor Angiogenesis: Brothers in Arms with GRK2?

There is cumulative evidence that changes in GRKs are relevant events in tissue-specific tumor progression, as their key roles in the regulation of many cell processes and signaling pathways can be conditionally harnessed by transformed cells depending on the tumor GPCR profile, oncogenic pathways, and environmental insults. The impact of different GRKs on tumor angiogenesis might be related to the modulation of GPCR activity, either by triggering receptor desensitization or by mediating G-protein independent receptor signaling. Numerous chemokines act as direct pro-angiogenic factors, whereas other GPCR agonists (catecholamines, S1P, or thrombin) stimulate production of master angiogenic drivers such as HIF1α or VEGF. The few studies addressing the role of GRKs in tumor angiogenesis have focused on the consequences of overall changes in GRK expression either in the transforming cell itself or in the host tumor tissue, but not specific alterations in the vascular component of the tumor. As such, endothelial GRK2 is the only isoform that has been directly implicated in the control of tumor angiogenesis.

In terms of other GRKs, downregulation of GRK3 has been correlated with increased proliferation of glioblastoma cells, both in a cell-autonomous manner and through a paracrine, endothelial-mediated effect. Conversely, increased GRK3 expression has been reported in prostate tumors that require this kinase for survival and proliferation of the transformed cells, whereas its overexpression fosters primary tumor growth and metastasis through the induction of angiogenesis. However, whether vascular GRK3 expression is altered or required to support angiogenesis in different tumors has not been addressed. Alternatively, expression of GRK5 (but not of GRK2) in endothelial cells attenuates the production and secretion of several proangiogenic cytokines by inhibiting NFkB transcriptional activity, which provokes impaired in vitro tube formation and in vivo angiogenesis in models of wound healing and chronic ischemia. These results suggest that vascular GRK5 levels might influence tumor angiogenesis. Interestingly, intratumor administration of a GRK5-based inhibitor of NFkB activity impairs the formation of tumor vascularization. However, the tumor component (tumor cells or vascular cells) involved in the antitumoral properties of GRK5-derived constructs and the cellular dosage of GRK5 in such tumor components remain unknown.

Furthermore, xenograft tumors implanted in systemic GRK6 knockout mice grow faster and more aggressively and with greater intratumor microvascular densities, which correlates with increased immune cell infiltration of myeloid origin and higher levels of stromal MMP9 and MMP2 metalloproteases. GRK6 deficiency blunted CXCR2 desensitization, suggesting that enhanced tumor growth might be a consequence of improved chemotactic motility, tumor homing, and protumoral neutrophil activity in these animals. However, GRK6 deficiency may also affect the proangiogenic function of the vascular cells and, indeed, GRK6 expression has been reported to be confined to vascular structures in some tumor tissues. Moreover, vascular ECs are one of the CXCR2-positive cellular components in the tumor stroma, and endothelial activation of CXCR2 augments the rate of angiogenesis. Therefore, it is possible that downregulation of vascular GRK2 in tumors might coexist with alterations in the profile of other GRKs, which would together shape a protumoral vasculature. Interestingly, a compensatory increase in expression of the closely related GRK3 isoform was not detected in mouse lung endothelial cells from global GRK2 hemizygous mice, whereas expression of GRK6 was modestly decreased.
Concluding Remarks and Perspectives

A decrease in endothelial GRK2 has a pivotal effect by contributing critically to the impaired pericyte–endothelial cell–cell interactions that characterize the immature tumor vasculature, thereby favoring vessel instability, increased permeability, and enhanced access of different cell types to the tumor in order to promote disease progression. Remarkably, vascular GRK2 is specifically downregulated in intratumoral vessels, whereas vessels in the normal tissue surrounding the tumor or in benign lesions retain kinase expression. Tumor-driven downregulation of endothelial GRK2 harnesses the role of GRK2 in vessel formation and stability in order to generate a microenvironment permissive for cancer progression. This challenging notion may have important pathophysiological implications and should prompt further studies to assess its feasibility as a novel marker of pathological vasculature and as a potential target for therapeutic strategies aimed at vessel normalization in cancer. The fact that GRK2 represents a common signaling hub for many receptors involved in endothelial GRK2 downregulation ameliorate tumor growth or aggressiveness, and does GRK2 upregulation have the opposite effect in vascular remodeling? What are the relevant GRK2-interacting proteins involved in vessel maturation? Likewise, the precise contribution of GRK2 kinase activity to different aspects of vascular remodeling remains to be determined. While it is attractive to anticipate that vessel normalization by preventing the reduction in GRK2 might divert a tumor toward a dormant state, it is also tempting to suggest that a potential synergistic effect of GRK2 depletion and antiangiogenic therapies based on ALK1 blockade could successfully trigger complete vessel regression. Conversely, it is unclear whether steady-state levels of endothelial GRK2 are related to metastasis. Cancer progression is characterized by the recruitment of macrophages to tumor tissues, a step fostered by vascular GRK2 downmodulation, and to premetastatic niches, where they condition the secondary localization of tumor cells. This latter step could also be facilitated in the context of reduced GRK2 expression.

Finally, epidemiological and clinical studies have shown that various chronic inflammatory diseases predispose patients to the risk of cancer, as noted for colorectal cancer in patients with Crohn’s disease or ulcerative colitis, or pancreatic cancer in patients with chronic pancreatitis, among others. In this regard, pathological angiogenesis in major inflammatory bowel conditions (ulcerative colitis and Crohn’s disease) and in other inflammatory processes, such as rheumatoid arthritis or psoriasis, is potentially a key factor in perpetuating disease. Remarkably, it is well documented that GRK2 levels are decreased in human patients suffering from inflammatory diseases (multiple sclerosis, rheumatoid arthritis, sepsis), suggesting that suppressed GRK2 levels might be important for long-term immaturity of the vascular system and cancer risk.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Funding

Our laboratory is funded by grants from Ministerio de Educación y Ciencia (SAF2011–23800), Fundación Ramón Areces, The Cardiovascular Network (RECAVA) of Ministerio Sanidad y Consumo-Instituto Carlos III (RD12/0042/0012), Comunidad de Madrid Indisnet Network (S2011/BMD-2332) to F.M., and Fundación Eugenio Rodríguez Pascual, Fundación Ramón Areces, ISS–PIE, and Instituto de Salud Carlos III (PI11/00859) to P.P.

References

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298–307; PMID:21593862; http://dx.doi.org/10.1038/ nature10144
2. Weiss SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011; 17:1559–70; PMID:22064426; http://dx.doi.org/10.1038/nm.2537
3. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutical aspects of angiogenesis. Cell 2011; 146:873–87; PMID:21925313; http://dx.doi.org/10.1016/j.cell.2011.08.039
4. Watarai K, Nakaya M, Kurose H. Multiple functions of G protein-coupled receptor kinases. J Mol Signal 2011; 6:1; PMID:21593862; http://dx.doi.org/10.1038/nm.2537
5. Penela P, Murga C, Ribas C, Lafarga V, Mayor F, Jr. The complex G protein-coupled receptor kinase 2 (GRK2) interactome unveils new physiopathological targets. Br J Pharmacol 2010; 160:821–32; PMID:20595801; http://dx.doi.org/10.1111/j.1366-5371.2010.00727.x
6. Rosv V, Carmona R, Munoz-Chapuli R, Mendiola M, Nogues L, Reglero C, Miguel-Martín M, García-Escudero R, Dorn GW, 2nd, Hardisson D, et al. Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2. J Clin Invest 2013; 123:4714–30; PMID:24135140; http://dx.doi.org/10.1172/JCI6733
7. van Meerten LA, Goumans MJ, ten Dijke P. TGF-beta receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. Curr Pharm Biotechnol 2011; 12:2108–20; PMID:21619934; http://dx.doi.org/10.2174/138920111798808338
8. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P. Actin regulator of pericyte function and vessel maturation. Cold Spring Harb Perspect Med 2012; 4:1; PMID:22355796; http://dx.doi.org/10.1172/JCI32479
9. No potential conflicts of interest were disclosed.

www.landesbioscience.com Molecular & Cellular Oncology e969166-9
15. Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. Recent Results Cancer Res 2010; 180:103-52; PMID:19789573; http://dx.doi.org/10.1007/978-3-540-78281-0_7

16. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003; 314:15-23; PMID:12888993; http://dx.doi.org/10.1007/s00441-003-0475-x

17. Lindblom P, Gerhardt H, Liebner S, Abramsson A, Engvall E, Håkanson R, Backstrom M, Fredrikson S, Landegren U, Nystrom HC, et al. Endothelial PDGF-BB retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003; 17:1835-40; PMID:12897953; http://dx.doi.org/10.1101/gad.266803

18. Taylor LM, Khachigian LM. Induction of platelet-derived growth factor-B-chain expression by transforming growth factor-beta involves transactivation by Smad2. J Biol Chem 2000; 275:16709-16; PMID:10828062; http://dx.doi.org/10.1074/jbc.275.22.16709

19. Ho J, Cocolakis E, Dumas VM, Posner BL, Laporte SA, Lebrun JG. The G-protein-coupled receptor kinase-2 is a sprout-inducing antagonist of TGFbeta signal transduction. EMBO J 2005; 24:3247-3258; PMID:16121194; http://dx.doi.org/10.1038/sj.emboj.7600794

20. David L, Mallet C, Mazeroni B, Betsholtz C. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007; 120:964-72; PMID:17311849; http://dx.doi.org/10.1242/jcs.024940

21. Maller C, Vinter D, Feige JJ, Bailly S. TGFbeta1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic PM. Kavale et al. development model: respective contribution of ALK1 and ALKS. Stem Cells 2006; 24:2420-7; PMID:17071858; http://dx.doi.org/10.1634/stemcells.2005-0494

22. Hall K, Ran S. Regulation of tumor angiogenesis by the local microenvironment. Front Biosci (Landmark Ed) 2010; 15:19-215; PMID:20206315; http://dx.doi.org/10.2741/3615

23. Chakraborty D, Sarkar C, Basu B, Dasgupta PS, Basu S. Catecholamines regulate tumor angiogenesis. Cancer Res 2009; 69:3727-30; PMID:19398306; http://dx.doi.org/10.1158/0008-5472.CAN-08-2489

24. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie-2 expressing monocytoid: role of tumor angiogenesis and therapeutic implications. Curr Hematol Malig Rev 2007; 28:519-24; PMID:17981504; http://dx.doi.org/10.1016/j.chmr.2007.09.004

25. Penela P, Ribas C, Mayor F, Jr. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases (GRKs) associated with hypoxic vascular disease. Cardiovasc Res 2006; 70:46-56; PMID:16288730

26. Ramos-Ruiz R, Penela P, Penn RB, Mayor F, Jr. Analysis of the human G protein-coupled receptor kinase 2 (GRK2) gene promoter: regulation by signal transduction systems in aortic smooth muscle cells. Circulation 2007; 110:2083-9; PMID:17093531; http://dx.doi.org/10.1161/01.CIR.101.17.2083

27. Karagiannis GS, Pavlou MF, Diamandis EP. Cancer tumour angiogenesis and therapeutic implications. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2010; 10:313-20; PMID:20375432; http://dx.doi.org/10.1038/nrc2807

28. Harris DM, Cohn HH, Pesant S, Eckhard AD. GPCR signalling in hypertension: role of GRKs. Clin Sci (Lond) 2008; 115:79-89; PMID:18593382; http://dx.doi.org/10.1042/CS20070442

29. Dorn GW, 2nd. GRK1: G-protein signaling in cardiovascular disease. J Mol Med (Berl) 2008; 86:455-61; PMID:18292955; http://dx.doi.org/10.1007/s11845-009-0457-0

30. Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 2011; 50:785-92; PMID:20806067; http://dx.doi.org/10.1016/j.yjmcc.2010.08.014

31. Malet-Perez J, Rathz DA, Petreeshvaka NY, Hahn HS, Wagoner LE, Schwarz A, Dorn GW, Ligger SB. Beta-adrenergic receptor polymorphisms confer differential functional and predispunction to heart failure. Nat Med 2003; 9:1300-5; PMID:12845227; http://dx.doi.org/10.1038/nmeth.510

32. Iacarrino G, Ciccirelli M, Sorrentino D, Galasso G, Campanile A, Santulli G, Cippolotta E, Cerulo V, Liguori M, Arbones GG, Jauch-Chara K. Ischemic neurogenesis is enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005; 97:118-29; PMID:16259589; http://dx.doi.org/10.1161/01.RES.0000191541.04678.bf

33. Galasso G, De Rosa R, Ciccirelli M, Sorrentino D, Del Giudice C, Strisciuglio T, De Biase C, Luciano R, Piccolo R, Pieri A, et al. beta2-Adrenergic receptor stimulation improves endothelial progenitor cell-mediated ischemic neurogenesis. Circ Res 2013; 112:1026-34; PMID:23438295; http://dx.doi.org/10.1161/CIRCRESAHA.111.300152

34. Ji Y, Chen S, Xiao Z, Zheng S, Li K, adrenergic receptor signaling in the proliferation of hemangioendothelial derived endothelial cells. Cell Division 2013; 8:1-12; PMID:23286511; http://dx.doi.org/10.1186/1747-1028-8-1

35. Ji Y, Chen S, Li K, Xiao Z, Zheng S, Xu T. The role of beta-adrenergic receptor signaling in the proliferation of hemangioendothelial derived endothelial cells. Cell Division 2013; 8:1-12; PMID:23286511; http://dx.doi.org/10.1186/1747-1028-8-1
